TY  - CONF
AU  - Obradović, Bojana
AU  - Stojkovska, Jasmina
AU  - Zvicer, Jovana
AU  - Milivojević, Milena
AU  - Janković, Radmila
AU  - Dragoj, Miodrag
AU  - Jančić, Ivan
PY  - 2024
UR  - https://www.ache-pub.org.rs/index.php/HemInd/article/view/1265
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2365
AB  - Development of novel, effective, and safe anti-tumor drugs is still a slow and cumbersome process, which is often attributed to weaknesses of current preclinical assays and low correlation of the preclinical in vitro and in vivo data with the results obtained in clinical trials. Consequently, there is a clear need for development of more reliable in vitro three dimensional (3D) tumor models, which will capture key features of the in vivo tumor cell microenvironment and provide drug testing results relevant for human patients. The aim of the project “Biomimetic tumor engineering to enhance drug discovery – BioengineeredTumor” funded by the Science Fund of the Republic of Serbia is to develop 2 novel, simple and robust 3D models for cultures of carcinoma and osteosarcoma cells by applying systematic and integrated methodology to comprehensively define the key model components. In specific, the aim is to use different human and animal cancer cell lines in conjunction with alginate-based biomaterials as artificial extracellular matrices imitating tumor environments and to cultivate the obtained constructs in perfusion bioreactors providing enhanced transport of nutrients, gases and biochemical signals to the cells as well as adequate levels of hydrodynamic shear stresses. Thus, the strategic goal is to establish an adaptable platform suited to the use by scientists without technical expertise for long-term in vitro studies of cancer cells for applications in anti-cancer drug discovery and validation, development of personalized medical treatments, and cancer research.
C3  - Hemijska industrija (Chemical Industry)
T1  - Biomimetic tumor engineering to enhance drug discovery - BioengineeredTumor
EP  - 22
IS  - 1S
SP  - 22
VL  - 78
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2365
ER  - 

@conference{
author = "Obradović, Bojana and Stojkovska, Jasmina and Zvicer, Jovana and Milivojević, Milena and Janković, Radmila and Dragoj, Miodrag and Jančić, Ivan",
year = "2024",
abstract = "Development of novel, effective, and safe anti-tumor drugs is still a slow and cumbersome process, which is often attributed to weaknesses of current preclinical assays and low correlation of the preclinical in vitro and in vivo data with the results obtained in clinical trials. Consequently, there is a clear need for development of more reliable in vitro three dimensional (3D) tumor models, which will capture key features of the in vivo tumor cell microenvironment and provide drug testing results relevant for human patients. The aim of the project “Biomimetic tumor engineering to enhance drug discovery – BioengineeredTumor” funded by the Science Fund of the Republic of Serbia is to develop 2 novel, simple and robust 3D models for cultures of carcinoma and osteosarcoma cells by applying systematic and integrated methodology to comprehensively define the key model components. In specific, the aim is to use different human and animal cancer cell lines in conjunction with alginate-based biomaterials as artificial extracellular matrices imitating tumor environments and to cultivate the obtained constructs in perfusion bioreactors providing enhanced transport of nutrients, gases and biochemical signals to the cells as well as adequate levels of hydrodynamic shear stresses. Thus, the strategic goal is to establish an adaptable platform suited to the use by scientists without technical expertise for long-term in vitro studies of cancer cells for applications in anti-cancer drug discovery and validation, development of personalized medical treatments, and cancer research.",
journal = "Hemijska industrija (Chemical Industry)",
title = "Biomimetic tumor engineering to enhance drug discovery - BioengineeredTumor",
pages = "22-22",
number = "1S",
volume = "78",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2365"
}

Obradović, B., Stojkovska, J., Zvicer, J., Milivojević, M., Janković, R., Dragoj, M.,& Jančić, I.. (2024). Biomimetic tumor engineering to enhance drug discovery - BioengineeredTumor. in Hemijska industrija (Chemical Industry), 78(1S), 22-22.
https://hdl.handle.net/21.15107/rcub_imagine_2365

Obradović B, Stojkovska J, Zvicer J, Milivojević M, Janković R, Dragoj M, Jančić I. Biomimetic tumor engineering to enhance drug discovery - BioengineeredTumor. in Hemijska industrija (Chemical Industry). 2024;78(1S):22-22.
https://hdl.handle.net/21.15107/rcub_imagine_2365 .

Obradović, Bojana, Stojkovska, Jasmina, Zvicer, Jovana, Milivojević, Milena, Janković, Radmila, Dragoj, Miodrag, Jančić, Ivan, "Biomimetic tumor engineering to enhance drug discovery - BioengineeredTumor" in Hemijska industrija (Chemical Industry), 78, no. 1S (2024):22-22,
https://hdl.handle.net/21.15107/rcub_imagine_2365 .

TY  - JOUR
AU  - Jančić, Ivan
AU  - Šefik-Bukilica, Mirjana
AU  - Živojinović, Slađana
AU  - Damjanov, Nemanja
AU  - Spasovski, Vesna
AU  - Kotur, Nikola
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, Sonja
AU  - Bufan, Biljana
AU  - Arsenović-Ranin, Nevena
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/837
AB  - Uvod: Genetički faktori su značajni za predviđanje ishoda lečenja bolesnika sa reumatoidnim artritisom (RA). Cilj studije bio je da se ispita uticaj-308G/A TNF-α (rs 1800629) i -174G/C IL-6 (rs1800795) promotorskih polimorfizama na terapijski odgovor na etanercept. Metode: U studiju su bila uključena 73 pacijenta sa aktivnim RA. Terapijski odgovor je procenjivan posle 6 i 12 meseci terapije po kriterijumima Evropske lige protiv reumatizma. Genotipizacija pacijenata za polimorfizme -308G/A TNF-α i -174G/C IL-6 urađena je PCR-RFLP metodom i procenjivan je uticaj genotipova na odgovor na etanercept. Rezultati: Nije bilo razlike u procentu respondera (pacijenti kod kojih se DAS28 popravio  gt  1,2) između pacijenata sa TNF-α -308GG, GA i AA genotipom ni posle 6 ni posle 12 meseci tretmana. Posle 12 meseci lečenja procenat respondera je bio značajno veći kod pacijenata sa IL-6 -174GG u odnosu na pacijente sa GC ili CC genotipom (p= 0,006, x2 test). Poređenje pacijenata prema kombinovanim IL-6/TNF-α genotipovima pokazalo je da je IL-6 -174GG / TNF-α -308GG genotip učestaliji kod respondera u odnosu na druge kombinovane genotipove (p= 0.022, x2 test). Tačnije, svi pacijenti sa kombinovanim IL-6 -174GG / TNF-α -308GG genotipom bili su responderi posle 12 meseci terapije etanerceptom. Zaključak: Studija pokazuje da bolesnici sa genotipovima koji se povezuju sa manjom produkcijom TNF-α i IL-6 najbolje odgovaraju na terapiju etanerceptom.
AB  - Background: The study was undertaken to assess the influence of functional -308G /A TNF-α (rs 1800629) and -174G/C IL-6 (rs1800795) promoter polymorphisms on the therapeutic response to etanercept, a TNF-α blocker, in patients with rheumatoid arthritis (RA). Methods: Seventy-three patients suffering from active RA were studied, at baseline and 6 and 12 months after therapy. The therapeutic response was estimated according to the European League Against Rheumatism response criteria. Patients were genotyped for -308G /A TNF-α and -174G/C IL-6 polymorphisms by the PCR-RFLP method, and the influence of genotype on etanercept response was assessed. Results: No difference in the percentage of responders (patients who had DAS28 improvement  gt  1.2) between patients with the TNF-α -308GG and GA and AA genotype was detected after 6 and 12 months of treatment. After 12 months of treatment the percentage of responders was significantly increased in patients with the IL-6 -174GG genotype compared with those with the GC or CC genotype (p=0.006 by Chi-square test). Evaluation of the patients according to their combined IL-6/TNF-α genotypes showed that patients with the IL-6 -174GG / TNF-α -308GG genotype were more frequent among the responders compared to those with other combined genotypes (p=0.022 by Chisquare test). More precisely, all patients with the combined IL-6 -174GG / TNF-α -308GG genotype were responders after 12 months of etanercept treatment. Conclusions: The study suggests that patients who are genetically low TNF-α and IL-6 producers are the best responders to etanercept therapy.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Uticaj polimorfizama TNF-α (-308G/A) i IL-6 (-174G/C) gena na terapijski odgovor na etanercept u reumatoidnom artritisu
T1  - Influence of promoter polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) genes on therapeutic response to etanercept in rheumatoid arthritis
EP  - 421
IS  - 4
SP  - 414
VL  - 34
DO  - 10.2478/jomb-2014-0060
ER  - 

@article{
author = "Jančić, Ivan and Šefik-Bukilica, Mirjana and Živojinović, Slađana and Damjanov, Nemanja and Spasovski, Vesna and Kotur, Nikola and Karan-Đurašević, Teodora and Pavlović, Sonja and Bufan, Biljana and Arsenović-Ranin, Nevena",
year = "2015",
abstract = "Uvod: Genetički faktori su značajni za predviđanje ishoda lečenja bolesnika sa reumatoidnim artritisom (RA). Cilj studije bio je da se ispita uticaj-308G/A TNF-α (rs 1800629) i -174G/C IL-6 (rs1800795) promotorskih polimorfizama na terapijski odgovor na etanercept. Metode: U studiju su bila uključena 73 pacijenta sa aktivnim RA. Terapijski odgovor je procenjivan posle 6 i 12 meseci terapije po kriterijumima Evropske lige protiv reumatizma. Genotipizacija pacijenata za polimorfizme -308G/A TNF-α i -174G/C IL-6 urađena je PCR-RFLP metodom i procenjivan je uticaj genotipova na odgovor na etanercept. Rezultati: Nije bilo razlike u procentu respondera (pacijenti kod kojih se DAS28 popravio  gt  1,2) između pacijenata sa TNF-α -308GG, GA i AA genotipom ni posle 6 ni posle 12 meseci tretmana. Posle 12 meseci lečenja procenat respondera je bio značajno veći kod pacijenata sa IL-6 -174GG u odnosu na pacijente sa GC ili CC genotipom (p= 0,006, x2 test). Poređenje pacijenata prema kombinovanim IL-6/TNF-α genotipovima pokazalo je da je IL-6 -174GG / TNF-α -308GG genotip učestaliji kod respondera u odnosu na druge kombinovane genotipove (p= 0.022, x2 test). Tačnije, svi pacijenti sa kombinovanim IL-6 -174GG / TNF-α -308GG genotipom bili su responderi posle 12 meseci terapije etanerceptom. Zaključak: Studija pokazuje da bolesnici sa genotipovima koji se povezuju sa manjom produkcijom TNF-α i IL-6 najbolje odgovaraju na terapiju etanerceptom., Background: The study was undertaken to assess the influence of functional -308G /A TNF-α (rs 1800629) and -174G/C IL-6 (rs1800795) promoter polymorphisms on the therapeutic response to etanercept, a TNF-α blocker, in patients with rheumatoid arthritis (RA). Methods: Seventy-three patients suffering from active RA were studied, at baseline and 6 and 12 months after therapy. The therapeutic response was estimated according to the European League Against Rheumatism response criteria. Patients were genotyped for -308G /A TNF-α and -174G/C IL-6 polymorphisms by the PCR-RFLP method, and the influence of genotype on etanercept response was assessed. Results: No difference in the percentage of responders (patients who had DAS28 improvement  gt  1.2) between patients with the TNF-α -308GG and GA and AA genotype was detected after 6 and 12 months of treatment. After 12 months of treatment the percentage of responders was significantly increased in patients with the IL-6 -174GG genotype compared with those with the GC or CC genotype (p=0.006 by Chi-square test). Evaluation of the patients according to their combined IL-6/TNF-α genotypes showed that patients with the IL-6 -174GG / TNF-α -308GG genotype were more frequent among the responders compared to those with other combined genotypes (p=0.022 by Chisquare test). More precisely, all patients with the combined IL-6 -174GG / TNF-α -308GG genotype were responders after 12 months of etanercept treatment. Conclusions: The study suggests that patients who are genetically low TNF-α and IL-6 producers are the best responders to etanercept therapy.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Uticaj polimorfizama TNF-α (-308G/A) i IL-6 (-174G/C) gena na terapijski odgovor na etanercept u reumatoidnom artritisu, Influence of promoter polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) genes on therapeutic response to etanercept in rheumatoid arthritis",
pages = "421-414",
number = "4",
volume = "34",
doi = "10.2478/jomb-2014-0060"
}

Jančić, I., Šefik-Bukilica, M., Živojinović, S., Damjanov, N., Spasovski, V., Kotur, N., Karan-Đurašević, T., Pavlović, S., Bufan, B.,& Arsenović-Ranin, N.. (2015). Uticaj polimorfizama TNF-α (-308G/A) i IL-6 (-174G/C) gena na terapijski odgovor na etanercept u reumatoidnom artritisu. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 34(4), 414-421.
https://doi.org/10.2478/jomb-2014-0060

Jančić I, Šefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, Kotur N, Karan-Đurašević T, Pavlović S, Bufan B, Arsenović-Ranin N. Uticaj polimorfizama TNF-α (-308G/A) i IL-6 (-174G/C) gena na terapijski odgovor na etanercept u reumatoidnom artritisu. in Journal of Medical Biochemistry. 2015;34(4):414-421.
doi:10.2478/jomb-2014-0060 .

Jančić, Ivan, Šefik-Bukilica, Mirjana, Živojinović, Slađana, Damjanov, Nemanja, Spasovski, Vesna, Kotur, Nikola, Karan-Đurašević, Teodora, Pavlović, Sonja, Bufan, Biljana, Arsenović-Ranin, Nevena, "Uticaj polimorfizama TNF-α (-308G/A) i IL-6 (-174G/C) gena na terapijski odgovor na etanercept u reumatoidnom artritisu" in Journal of Medical Biochemistry, 34, no. 4 (2015):414-421,
https://doi.org/10.2478/jomb-2014-0060 . .